Dynamic cost-benefit analysis of drug substitution programs
From MaRDI portal
Recommendations
- Modeling General Practitioners’ Total Drug Costs through GAMLSS and Collective Risk Models
- Optimal Dynamic Allocation of Treatment and Enforcement in Illicit Drug Control
- A bargaining approach for resolving the tradeoff between beneficial and harmful drug responses
- A dynamic model of drug initiation: Implications for treatment and drug control
- Optimal allocation of drug control efforts: A differential game analysis
- Employing super-efficiency analysis as an alternative to DEA: an application in outpatient substance abuse treatment
- Optimal treatments in cost-effectiveness analysis in the presence of covariates: improving patient subgroup definition
- Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective
- Design of incentive programs for optimal medication adherence in the presence of observable consumption
Cites work
- A complete characterization of optimal growth paths in an aggregated model with a non-concave production function
- Optimal Control of Drug Epidemics: Prevent and Treat—But Not at the Same Time?
- Optimal Dynamic Allocation of Treatment and Enforcement in Illicit Drug Control
- Optimal Growth with a Convex-Concave Production Function
- The General Instability of a Class of Competitive Growth Processes
Cited in
(3)
This page was built for publication: Dynamic cost-benefit analysis of drug substitution programs
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q850913)